GlassScriptPhysician profile
Bridget R Briggs
NPI 1568436343
$115,995.65
in general payments reported to CMS, 2019-2025
53 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $14K · 2021: $28K · 2022: $15K · 2023: $8,394 · 2024: $16K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $7,024 · Travel and Lodging: $4,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,506.25 |
| Food and Beverage | $7,024.02 |
| Travel and Lodging | $4,171.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $84,450.23 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $23,955.42 | 2019-2025 | Repatha, Repatha, Otezla |
| Allergan, INC. | $2,061.86 | 2019-2021 | |
| Novo Nordisk INC | $1,053.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $557.95 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $513.61 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $471.34 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $348.69 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.33 | 2020-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.52 | 2019-2025 | Xifaxan |
| Horizon Therapeutics Plc | $144.60 | 2019-2023 | Tepezza |
| Pfizer INC. | $116.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $115.66 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $108.58 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Intuitive Surgical, INC. | $105.24 | 2019 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.